Targeted drug trial aims to tame Slow-Growing lymphoma with fewer side effects
NCT ID NCT07372365
Summary
This study is testing a new treatment approach for adults with marginal zone lymphoma (MZL), a slow-growing blood cancer, who haven't had prior systemic therapy. It combines a short course of standard chemotherapy with a longer period of a newer, targeted pill called orelabrutinib, hoping to better control the disease. Researchers will monitor how well the treatment works and its safety over time, including a maintenance phase lasting up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.